KR100622285B1 - 나노분산액을 사용한 약제학적 최종 제형의 제조 방법, 나노분산액의 예비상 및 나노분산액 - Google Patents

나노분산액을 사용한 약제학적 최종 제형의 제조 방법, 나노분산액의 예비상 및 나노분산액 Download PDF

Info

Publication number
KR100622285B1
KR100622285B1 KR1019990016580A KR19990016580A KR100622285B1 KR 100622285 B1 KR100622285 B1 KR 100622285B1 KR 1019990016580 A KR1019990016580 A KR 1019990016580A KR 19990016580 A KR19990016580 A KR 19990016580A KR 100622285 B1 KR100622285 B1 KR 100622285B1
Authority
KR
South Korea
Prior art keywords
polyethoxylated
delete delete
nanodispersion
nanodispersions
components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019990016580A
Other languages
English (en)
Korean (ko)
Other versions
KR19990088156A (ko
Inventor
주퍼작소안드레아스베르너
베더한스게오르그
휘글린디트마
뢰딩요아힘프리드리히
Original Assignee
시바 스페셜티 케미칼스 홀딩 인크.
페지파크트 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시바 스페셜티 케미칼스 홀딩 인크., 페지파크트 아게 filed Critical 시바 스페셜티 케미칼스 홀딩 인크.
Publication of KR19990088156A publication Critical patent/KR19990088156A/ko
Application granted granted Critical
Publication of KR100622285B1 publication Critical patent/KR100622285B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019990016580A 1998-05-11 1999-05-10 나노분산액을 사용한 약제학적 최종 제형의 제조 방법, 나노분산액의 예비상 및 나노분산액 Expired - Fee Related KR100622285B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98810422.0 1998-05-11
EP98810422 1998-05-11

Publications (2)

Publication Number Publication Date
KR19990088156A KR19990088156A (ko) 1999-12-27
KR100622285B1 true KR100622285B1 (ko) 2006-09-11

Family

ID=8236078

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019990016580A Expired - Fee Related KR100622285B1 (ko) 1998-05-11 1999-05-10 나노분산액을 사용한 약제학적 최종 제형의 제조 방법, 나노분산액의 예비상 및 나노분산액

Country Status (20)

Country Link
US (2) US7081253B2 (https=)
EP (1) EP0956853B1 (https=)
JP (1) JP4755742B2 (https=)
KR (1) KR100622285B1 (https=)
CN (1) CN1220483C (https=)
AR (1) AR019274A1 (https=)
AT (1) ATE312597T1 (https=)
AU (1) AU767896B2 (https=)
BR (1) BRPI9902068B8 (https=)
CZ (1) CZ166999A3 (https=)
DE (1) DE59912910D1 (https=)
ES (1) ES2253871T3 (https=)
HU (1) HUP9901570A2 (https=)
ID (1) ID22565A (https=)
MY (1) MY133019A (https=)
PL (1) PL332934A1 (https=)
RU (1) RU2224505C2 (https=)
SG (1) SG71923A1 (https=)
TW (1) TWI241915B (https=)
ZA (1) ZA993200B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908309D0 (en) * 1999-04-12 1999-06-02 Phares Pharm Res Nv Lipid aggregate forming compositions and their use
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
TW586945B (en) * 2001-01-12 2004-05-11 Novartis Ag Lens care product containing dexpanthenol
US20030113366A1 (en) * 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
RU2200558C1 (ru) * 2002-04-23 2003-03-20 Нестерук Владимир Викторович Лекарственное средство, содержащее финастерид
AT6609U3 (de) * 2003-04-07 2004-04-26 Unipack Ges M B H Abfuell Und Verfahren zum herstellen einer klaren lecithin enthaltenden oralen zubereitung
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
WO2005117830A1 (en) * 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
TWI350183B (en) * 2003-12-31 2011-10-11 Ind Tech Res Inst A liposome and a preparation method
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
DE112006001898B4 (de) * 2005-07-21 2013-05-08 National Institute For Materials Science Vorrichtung zur Inhalation von Arzneimitteln
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
NZ572601A (en) 2006-03-29 2012-03-30 Univ Wayne State Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
JP4840031B2 (ja) 2006-08-31 2011-12-21 ソニー株式会社 ナビゲーション装置、ナビゲーション処理方法及びナビゲーション処理プログラム
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
CL2008000037A1 (es) * 2007-01-16 2008-10-10 Bayer Consumer Care Ag Solucion coloidal que comprende al menos un ingrediente activo, al menos una molecula formadora de membrana y al menos un componente espumante; procedimiento para fabricar la solucion coloidal; y su uso para tratar trastornos dermatologicos.
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
CN100536826C (zh) * 2007-12-28 2009-09-09 清华大学 一种绵羊油纳米乳液及其制备方法和应用
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
DE202010004750U1 (de) 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut
CN102277748A (zh) * 2010-06-12 2011-12-14 罗莱家纺股份有限公司 纳米维生素微胶囊整理剂的使用方法
KR101494594B1 (ko) * 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP3583954A1 (en) * 2018-06-19 2019-12-25 neubourg skin care GmbH Nanodispersions of birch bark extract, electrospun fibers containing such nanodispersions and their use for the treatment of wounds
EP4065108B1 (en) 2019-11-25 2025-08-06 The Johns Hopkins University Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors
CN111388744B (zh) * 2020-01-15 2021-05-18 华中科技大学 一种凝胶贮库及其制法与制备术后止血制剂的应用
CA3170810A1 (en) * 2020-02-11 2021-08-19 Advent Therapeutics Inc. Compositions of vitamin a palmitate, processes for their preparation, uses and methods comprising them
US20230310386A1 (en) * 2020-05-20 2023-10-05 Intervet Inc. Injectable pharmaceutical compositions and uses thereof
CA3185481A1 (en) * 2020-06-01 2021-12-09 Advent Therapeutics, Inc. Pharmaceutical compositions comprising insoluble active ingredients
MX2022016437A (es) 2020-06-30 2023-01-30 Chong Kun Dang Pharmaceutical Corp Composicion inyectable que comprende un analogo de gnrh.
WO2024165166A1 (en) 2023-02-10 2024-08-15 Tetra Pharm Technologies A cannabinoid-based o/w emulsification system for oral administration targeting endocannabinoid receptors
WO2024208434A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Pressurized nanoemulsion
WO2024208433A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960016908A (ko) * 1994-11-09 1996-06-17 베르너 발데크 제약학상 담체
KR960033470A (ko) * 1995-03-21 1996-10-22 베르너 발데크 정맥내 투여용 나노현탁액
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3150990A1 (de) 1981-12-23 1983-06-30 A. Nattermann & Cie GmbH, 5000 Köln Neue pflanzenschutzmittelsuspensionskonzentrate
US4675193A (en) * 1983-10-31 1987-06-23 Borden, Inc. Cheese-flavored substance and method of producing same
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
US4965357A (en) 1986-08-07 1990-10-23 Medice Chem.-Pharm. Fabrik Putter Gmbh & Co. Kg 2,5,6-substituted N1 -alkylpyrimidines
DE3852409T2 (de) 1987-01-27 1995-04-20 Vestar Inc Aus Phospholipiden bestehende Darreichungsform für wasserunlösliche Wirksubstanzen.
DE68917544T2 (de) 1988-06-20 1994-12-15 Shiseido Co Ltd Durchsichtiges Präparat.
CA1337397C (en) * 1988-09-29 1995-10-24 Hideo Nakajima Emulsified composition
FR2648462B1 (fr) 1989-06-15 1994-01-28 Oreal Procede pour ameliorer l'efficacite therapeutique de corticosteroides liposolubles et composition pour la mise en oeuvre de ce procede
CH677886A5 (https=) * 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
ZA925581B (en) * 1991-07-26 1993-05-14 Smithkline Beecham Corp Pharmaceutical microemulsions.
US5260065A (en) 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
CH685674A5 (de) 1993-12-19 1995-09-15 Marigen Sa Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit pharmakologisch wirksamen Estern von Apocarotinolen.
ES2094688B1 (es) * 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
PE52896A1 (es) * 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
WO1996037192A1 (en) * 1995-05-26 1996-11-28 Vesifact Ag Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids
DE19522693A1 (de) 1995-06-22 1997-01-02 Dianorm G Maierhofer Gmbh Zusammensetzung zur Herstellung feindisperser Systeme und Verfahren zu ihrer Herstellung
JP3508314B2 (ja) * 1995-08-18 2004-03-22 大正製薬株式会社 ビタミンｃを配合した液剤
AU7689996A (en) * 1995-12-12 1997-07-03 Vesifact Ag Cortisone spray for topical administration
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
DE59710082D1 (de) * 1996-12-13 2003-06-18 Vesifact Ag Baar Kosmetische Präparate in Form einer Nanodispersion
US6028067A (en) * 1997-12-05 2000-02-22 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
KR960016908A (ko) * 1994-11-09 1996-06-17 베르너 발데크 제약학상 담체
US5658898A (en) * 1994-11-09 1997-08-19 Ciba Geigy Corporation Intravenous solutions for a derivative of staurosporine
KR960033470A (ko) * 1995-03-21 1996-10-22 베르너 발데크 정맥내 투여용 나노현탁액

Also Published As

Publication number Publication date
EP0956853B1 (de) 2005-12-14
EP0956853A2 (de) 1999-11-17
AU2805099A (en) 1999-11-18
PL332934A1 (en) 1999-11-22
US7081253B2 (en) 2006-07-25
JP4755742B2 (ja) 2011-08-24
ID22565A (id) 1999-11-11
JPH11335266A (ja) 1999-12-07
HU9901570D0 (en) 1999-07-28
SG71923A1 (en) 2000-04-18
CN1235017A (zh) 1999-11-17
US7871642B2 (en) 2011-01-18
ATE312597T1 (de) 2005-12-15
RU2224505C2 (ru) 2004-02-27
BRPI9902068B8 (pt) 2021-05-25
MY133019A (en) 2007-10-31
TWI241915B (en) 2005-10-21
CZ166999A3 (cs) 1999-11-17
BR9902068A (pt) 2000-06-06
CN1220483C (zh) 2005-09-28
KR19990088156A (ko) 1999-12-27
EP0956853A3 (de) 2000-01-05
DE59912910D1 (de) 2006-01-19
AR019274A1 (es) 2002-02-13
AU767896B2 (en) 2003-11-27
BR9902068B1 (pt) 2014-10-29
US20060292191A1 (en) 2006-12-28
ZA993200B (en) 1999-11-11
ES2253871T3 (es) 2006-06-01
US20030190347A1 (en) 2003-10-09
HUP9901570A2 (hu) 2001-06-28

Similar Documents

Publication Publication Date Title
KR100622285B1 (ko) 나노분산액을 사용한 약제학적 최종 제형의 제조 방법, 나노분산액의 예비상 및 나노분산액
US5726164A (en) Nanosuspensions for intravenous administration
US5658898A (en) Intravenous solutions for a derivative of staurosporine
US6479540B1 (en) Compositions of tocol-soluble therapeutics
DE69935602T2 (de) Verabreichungssyteme für proteinarzneistoffe unter verwendung von membranmimetika
JP3202999B2 (ja) 肝移行性リポソーム製剤
WO1999044594A1 (fr) Emulsions huileuses destinees a etre administrees par inhalation
JPH02203A (ja) 薬物担体
JP2688235B2 (ja) 医薬物質含有脂肪乳剤の用時調製型キットおよび医薬物質含有脂肪乳剤の調製方法
JPH0145446B2 (https=)
DE60101370T2 (de) Pharmazeutische zusammensetzungen, die terbinafin enthalten
HU201873B (en) Process for producing lipide micromedium containing ibudilaste
EP1256337A1 (de) Verfahren und Zusammensetzungen zum Aufbringen eines Wirkstoffs auf ein Substrat
TWI911987B (zh) 含有傳明酸與維ａ酸的複方組合物
MXPA99004334A (es) Uso de nanodispersiones en formulaciones farmaceuticas finales
EP0467838A2 (de) Verfahren zur Herstellung einer injizierbaren Liposomendispersion
JPS61221114A (ja) 脂肪乳剤
JP2616240B2 (ja) 脂肪乳剤の製法
WO2002009670A1 (en) Liquid or semi-solid pharmaceutical excipient and pharmaceutical composition comprising the same
MXPA96001033A (en) Nanosuspensions for intraven administration
JPWO1999044594A1 (ja) 吸入投与用脂肪乳剤

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20120904

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20130829

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20140901

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20150730

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20160818

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170905

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170905